Miller Steve 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Aug 28, 2025
Insider Transaction Report
Form 4
Miller Steve
VP Development & Management
Transactions
- Sale
Common stock, par value $0.001 per share
2025-08-26$20.28/sh−115,000$2,332,200→ 949,663 total - Exercise/Conversion
Options to purchase common stock
2025-08-27−110,000→ 1,299,509 totalExercise: $2.24Exp: 2025-12-19→ Common Stock (110,000 underlying) - Exercise/Conversion
Common stock, par value $0.001 per share
2025-08-26$2.24/sh+115,000$257,600→ 1,064,663 total - Exercise/Conversion
Common stock, par value $0.001 per share
2025-08-27$2.24/sh+110,000$246,400→ 1,059,663 total - Exercise/Conversion
Options to purchase common stock
2025-08-26−115,000→ 1,409,509 totalExercise: $2.24Exp: 2025-12-19→ Common Stock (115,000 underlying)
Footnotes (3)
- [F1]Shares were sold on the open market to fund the exercise price and estimated taxes due from Reporting Person as a result of the exercise of the 225,000 stock options reported on Table II.
- [F2]Represents a weighted average sale price. Shares were sold in a range from $20.04 to $20.645 per share.
- [F3]Derivative Securities vested in three annual tranches beginning on December 18, 2019.